Global Leukapheresis Market Research Report 2027 - Competitive Analysis by Market Size, Share, Growth, Trends, Key Solutions, Demand & Opportunities

Leukapheresis is a medical procedure that involves separating and collecting white blood cells (leukocytes) from a person's blood. It's used for therapeutic and research purposes in various medical conditions like leukemia and lymphomas, either to decrease excessive white blood cell counts or to gather white blood cells for applications such as stem cell transplantation. During this procedure, blood is withdrawn from the patient's body through a needle or catheter, and it is then passed through a machine to isolate white blood cells, and then the rest of the blood is returned to the patient. This procedure allows for the selective removal or collection of specific types of white blood cells.

Major Factors Shaping the Global Leukapheresis Market: A Comprehensive Overview

Leukapheresis is a major tool in the segment of hematology and immunology, and it can further help in the treatment and management of certain blood-related disorders. The collected white blood cells can further be used in research studies and for developing therapies in immunology. Many key factors are shaping the growth of the global leukapheresis market. Firstly, the rising number of blood cancers, such as leukemia, lymphoma, and myeloma, underscores the major role of leukapheresis in treating these medical conditions.

Leukapheresis is often used to harvest hematopoietic stem cells for transplantation. The growing demand for stem cell transplants in multiple medical treatments triggers the market's growth, as leukapheresis is important in harvesting hematopoietic stem cells. Technological innovations in apheresis technology, providing more efficient and patient-friendly devices, improves the procedure's safety and effectiveness, boosting further adoption. Moreover, the growing healthcare expenditures in many countries enhances access to advanced medical procedures such as leukapheresis.

For instance,

In August 2023, Terumo Blood and Cell Technologies (Terumo BCT) disclosed that the US FDA has granted clearance for the Reveos Automated Whole Blood Processing System. This system is the first of its kind, available in USA and can process whole blood into platelets and other components in a single centrifugation cycle and is projected to enhance the blood and platelet supply for patients in USA.

An aging population, being at higher risk for blood-related diseases, drives the demand for leukapheresis. It has found its applications beyond oncology, such as in autoimmune disorders and organ transplantation, thus expanding its range of indications. Growing awareness on leukapheresis benefits, positive regulatory frameworks, and investments in R&D activities further drives the leukapheresis market's growth.

Send An Enquiry to Receive a FREE Sample Report on Leukapheresis Market @ https://meditechinsights.com/global-leukapheresis-market/

The Growing Role of Leukapheresis in Cell-Based Therapies and Further

Leukapheresis has gained importance as a therapeutic solution for various medical conditions, including leukemia, autoimmune ailments, and organ transplantation. The key factors triggering the leukapheresis market growth encompasses the growing cases of blood cancers, notably leukemia, rising utilization of leukopaks in research, and the global rise in blood donations. The growing number of leukemia further spurs the market demand, augmenting the use of leukapheresis machines and kits.
Leukapheresis has become an integral component of cell-based therapies, such as chimeric antigen receptor T-cell (CAR-T) therapy, which shows a tremendous potential in cancer treatment and contributes to the demand for leukapheresis. With a growing number of patients diagnosed with blood-related disorders, the necessity for leukapheresis procedures is on the rise, fueling demand for associated devices and services. Consistent research and development efforts aimed at improving leukapheresis procedures has led to the introduction of an efficient and automated devices, thus contributing to the market growth.

For instance,

In March 2023, Haemonetics Corporation revealed that it had obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation software of the Cell Saver® Elite®+ Autotransfusion System. The software upgrade, referred to as Intelligent Control, offers customers with tremendous improvements that streamline operations, enriching efficiency and the overall user experience.

The global socio-economic landscape was disrupted by COVID-19 pandemic. However, the pandemic also accelerated the research and development efforts, mainly in the segments of immunotherapy and vaccine development. Leukapheresis, playing an important role in collecting immune cells for these therapies, experienced a high demand due to COVID-19. The COVID-19 virus is characterized by a reduction in lymphocyte count, which are important, white blood cells essential for combating infections. When lymphocytes are in short supply, the body's ability to effectively counter the SARS-CoV-2 virus responsible for COVID-19 is compromised. Subsequently, the COVID-19 pandemic underscored the importance of leukapheresis in collecting convalescent plasma and immune cells, thus highlighting its role in pandemic preparedness.

The global leukapheresis market growth is triggered by the globalization of healthcare and improved access to specialized medical procedures in the emerging regions. Further, the growing trend towards personalized medicine, tailored to a patient's genetic and immunological profile, heightens the demand for leukapheresis to isolate specific cell populations. These factors then establish leukapheresis as an indispensable procedure in the segments of hematology and transfusion medicine.

North America Holds the Largest Share in the Global Leukapheresis Market

North America is projected to maintain its dominant position in the global leukapheresis market in the upcoming years. This is attributed due to the growing cases of cancer, rising demand for personalized therapies, fully-established healthcare infrastructures, and the presence of leading market players in the region. Whereas, the Asia-Pacific region is set to witness the highest CAGR during the forecast period. Other key factors such as the rising geriatric population, growing awareness on leukapheresis services, and heavy investments in the healthcare market are fuelling the growth of the Asia-Pacific market.

Competitive Landscape Analysis: Leukapheresis Market

Some of the key and established players operating in the global leukapheresis market are Asahi Kasei Medical Co. Ltd, Haemonetics Corporation, Terumo BCT INC., Miltenyi Biotec, Fresenius SE & Co. KGaA, Caltag Medsystems Limited, Macopharma SA, Lonza Group, Charles River Laboratories and Zen-Bio.

Aggressive Growth Strategies Adopted by the Leading Market Players to Establish Their Foothold in the Global Leukapheresis Market

All leading players operating in the global market are adopting aggressive growth strategies such as partnerships, takeovers, and new product launches to garner a larger market share.

For instance,

In September 2023, Fresenius Kabi revealed that it has entered into a partnership with Virginia Oncology Associates (VOA), in which VOA will take over the Ivenix Infusion System to administer medications to its patients. VOA is dedicated to serving patients with cancer and blood disorders, offering them quick access to innovative therapies and advanced technologies.

The global leukapheresis market is estimated to witness a healthy growth in the upcoming years due to an increasing number of cancer patients, growing investments in R&D activities, and aggressive growth strategies adopted by the global market players.

Send An Enquiry to Get Competitive Insights on the Leukapheresis Market Report @ https://meditechinsights.com/global-leukapheresis-market/

Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.